       Document 0997
 DOCN  M9650997
 TI    Sinusitis in children infected with human immunodeficiency virus:
       clinical characteristics, risk factors, and prophylaxis. National
       Institute of Child Health and Human Development Intravenous
       Immunoglobulin Clinical Trial Study Group.
 DT    9505
 AU    Mofenson LM; Korelitz J; Pelton S; Moye J Jr; Nugent R; Bethel J;
       Pediatric, Adolescent, and Maternal AIDS Branch, National; Institute of
       Child Health and Human Development, National; Institutes of Health,
       Bethesda, Maryland 20892-7510, USA.
 SO    Clin Infect Dis. 1995 Nov;21(5):1175-81. Unique Identifier : AIDSLINE
       MED/96126000
 AB    The clinical presentation, radiological and laboratory evaluation,
       treatment, and risk factors of sinusitis in a cohort of 376 human
       immunodeficiency virus (HIV)-infected children from a placebo-controlled
       clinical trial of intravenous immunoglobulin (IVIG) as prophylaxis for
       infections were examined. Ninety-five episodes of sinusitis were
       described in 60 patients; one-third of the patients had two or more
       episodes. Sinusitis episodes were commonly associated with nonspecific,
       chronic symptoms (67.4%, persistent nasal discharge; 54.7%, nocturnal or
       persistent cough), whereas symptoms more specific to acute sinusitis
       were less frequent (17.9%, headache or facial pain; 9.5%, periorbital
       swelling; 25.3%, temperature of > or = 102 degrees F; 9%, total white
       blood cell count of > or = 15,000/mm3). The sinuses primarily involved
       were the maxillary sinus (85.9%) and the ethmoidal sinus (42.3%); 36% of
       episodes involved two or more sinuses. Preceding respiratory infections
       did not appear to increase the risk of sinusitis, and CD4+ lymphocyte
       counts in children with and without sinusitis did not differ. Neither
       monthly IVIG prophylaxis nor three times weekly
       trimethoprimsulfamethoxazole prophylaxis for Pneumocystis carinii
       pneumonia decreased the risk of sinusitis. Sinusitis in HIV-infected
       children is most often subacute and recurrent. Evaluations of new
       modalities for prophylaxis for sinusitis are needed.
 DE    Anti-Infective Agents/PHARMACOLOGY  AIDS-Related Opportunistic
       Infections/*COMPLICATIONS/DIAGNOSIS/  PREVENTION & CONTROL  Case-Control
       Studies  Child  Child, Preschool  Cohort Studies  Female  Human
       Immunoglobulins, Intravenous/PHARMACOLOGY  Infant  Male  Recurrence
       Risk Factors  Sinusitis/*COMPLICATIONS/DIAGNOSIS/PREVENTION & CONTROL
       Support, U.S. Gov't, P.H.S.  Trimethoprim-Sulfamethoxazole
       Combination/PHARMACOLOGY  CLINICAL TRIAL  JOURNAL ARTICLE  RANDOMIZED
       CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

